Abstract Background Despite advancements in valve implantation devices, vascular access complications (VAC) remain a significant cause of morbidity and mortality
Transcatheter heart valves technologies
Transcatheter heart valves technologies
Predictors and Outcomes of Inappropriate Dosing of Direct Oral Anticoagulants in Patients Receiving Transcatheter Aortic Valve Implantation
Abstract Introduction Direct oral anticoagulant (DOAC) dose adjustment is based on age, renal function, and body weight. There is a
Transcatheter heart valves technologies
Transcatheter Aortic Valve Replacement: Full Unilateral Access Using the Ipsilateral Superficial Femoral Artery Is Effective
Abstract Background Access site complications are very common complications in transcatheter aortic valve replacement (TAVR). Usually, a second arterial sheath
Transcatheter heart valves technologies
Transcatheter Tricuspid Valve Replacement Following Tricuspid Edge‐To‐Edge‐Repair
Abstract Significant tricuspid regurgitation (TR) is seen as a relevant contributor of cardiac morbidity and mortality. Transcatheter tricuspid valve replacement
Transcatheter heart valves technologies
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
Abstract Background A substantial number of patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) experience adverse
Transcatheter heart valves technologies
Association Between Direct Oral Anticoagulant Score and Bleeding Events in Patients With Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: A Retrospective Multicenter Cohort Study
Abstract Background The Direct Oral Anticoagulant (DOAC) Score can predict bleeding risk in patients with atrial fibrillation taking DOACs; however,
Transcatheter heart valves technologies
Pacemaker Implantation for Low‐Grade Conduction Abnormalities After Balloon‐Expandable Transcatheter Aortic Valve Implantation
Abstract Introduction A frequent complication after TAVI are postinterventional conduction abnormalities requiring permanent pacemaker implantation. In this study, we analyzed
Transcatheter heart valves technologies
Lipoprotein(a) and High‐Sensitivity C‐Reactive Protein Compound the Risk of Hypoattenuating Leaflet Thickening After Transcatheter Aortic Valve Replacement
Abstract Background The mechanism for hypoattenuating leaflet thickening (HALT) after transcatheter aortic valve replacement is still not well elucidated, and
